|Description||MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the treatment of KRAS mutant colorectal cancer.|
|Brife Description||EGFR/PI3K inhibitor|
|Synonyms||MTX-211; MTX 211; MTX211; CS-7929; CS 7929; CS7929; HY-107364; HY 107364; HY107364; N-(2-chloro-5-(4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)pyridin-3-yl)methanesulfonamide|
|Solubility||Soluble in DMSO|
BMS-599626 Hydrochloride is a selective and efficacious orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases with potential antineoplastic ...
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...
Erlotinib is an EGFR inhibitor. The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth ...
Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...
PF 6274484 is a high affinity and potent covalent EGFR kinase inhibitor (Ki = 0.14 nM). It inhibits the autophosphorylation of wild-type EGFR in A549 cells and ...
RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.
BIBX 1382 dihydrochloride
BIBX 1382 dihydrochloride is a potent and selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM) with > 1000-fold lower po...
MTX-211 is a dual inhibitor of EGFR and PI3K, which plays important roles in the progression of KRAS mutant colorectal cancer. MTX-211 has the potential for the...